Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
|Articles|June 13, 2011
- Summer 2011
- Volume 10
- Issue 2
Summer Camp
Summer Camp
Advertisement
Looking for a nice place or camp to get away for a bit this summer? The website
Articles in this issue
over 15 years ago
Blog: Standing up to melanomaover 15 years ago
From Our Archives: Advance Directiveover 15 years ago
From Our Archives: Art & Healingover 15 years ago
Teenage Tan Bans Spreading Across Statesover 15 years ago
Prostate Cancer Prevention Drugs Get a “No” Voteover 15 years ago
The Health Care Law: Rhetoric and Realityover 15 years ago
Nonmelanoma Skin Cancerover 15 years ago
From Our Archives: Skin Cancerover 15 years ago
Risky InfectionsNewsletter
Stay up to date on cancer updates, research and education
SubscribeAdvertisement
Related to this article
Medicare's cap on out-of-pocket drug costs has made cancer pills more affordable, but premiums, formularies and prior authorization rules still vary widely. Here's a checklist.
After two cancer diagnoses and major surgery, a liver cancer survivor shares why asking questions, exploring treatment options and advocating for your care matter.
A custom mRNA vaccine is the first to succeed in a phase 3 trial. Learn how personalized cancer vaccines work and what to watch for at ESMO 2026.
A rising PSA after surgery or radiation can be frightening. Learn what biochemical recurrence means, which tests come next and your treatment options.
Three doctors dismissed Christine Kushner’s breast changes at 37. Trusting her gut and pushing for a mammogram helped save her life.
Six years after a B-cell ALL diagnosis at 21, William Yank shares how his view of therapy changed and why he is still working on his mental health.
A Phoenix man with metastatic castration-sensitive prostate cancer shares how back pain led to a PSA test and how his family helped him cope.
Advertisement
Advertisement